Sergio L. Pecorelli

Sergio L. Pecorelli's AcademicInfluence.com Rankings

Sergio L. Pecorelli

Philosophy

#6624

World Rank

#9688

Historical Rank

Logic

#3766

World Rank

#4972

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Sergio L. Pecorelli's Degrees

Doctorate Medicine University of Brescia
PhD Obstetrics and Gynecology University of Milan

Why Is Sergio L. Pecorelli Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Sergio L. Pecorelli's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium (2009) (1649)
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. (2010) (1291)
FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. (2000) (1196)
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. (2000) (1001)
Corrigendum to “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium” (2010) (893)
Carcinoma of the Ovary (2003) (832)
Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. (2006) (661)
Revised FIGO staging for carcinoma of the cervix (2009) (634)
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. (1995) (618)
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. (2003) (586)
Ovarian cancer: screening, treatment, and followup. (1995) (579)
Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. (2006) (526)
Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). (2008) (467)
Carcinoma of the corpus uteri (2003) (466)
Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. (2006) (443)
Carcinoma of the Cervix Uteri (2006) (440)
Carcinoma of the Corpus Uteri (2006) (431)
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). (2005) (425)
International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma. (2003) (411)
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy (2004) (307)
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma (2013) (260)
Interventional tools to improve medication adherence: review of literature (2015) (234)
FIGO staging of gynecologic cancer (1999) (228)
Gestational trophoblastic neoplasia, FIGO 2000 staging and classification (2003) (210)
In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDX1) (1996) (207)
Staging Classifications and Clinical Practice: Guidelines for Gynaecologic Cancers (2003) (200)
Staging Classifications and Clinical Practice: Guidelines for Gynaecologic Cancers (2003) (200)
FIGO staging classifications and clinical practice gudelines in the management of gynecologic cancers (2000) (197)
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu (2008) (188)
Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. (2005) (185)
Overexpression of HER-2/neu in uterine serous papillary cancer. (2002) (180)
Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment (2005) (179)
Induction of Human Papillomavirus-Specific CD4+ and CD8+ Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer (1999) (172)
Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+ Cytotoxic T Lymphocytes (2000) (172)
History of the FIGO cancer staging system (2008) (164)
Carcinoma of the ovary (2003) (159)
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients (2011) (156)
Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. (1995) (155)
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. (2000) (154)
Assessing COVID-19 vaccine literacy: a preliminary online survey (2020) (152)
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition (2016) (151)
Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. (2010) (140)
FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. (1999) (138)
Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial (2007) (131)
Effect of Transdermal Estradiol and Oral Conjugated Estrogen on C-Reactive Protein in Retinoid-Placebo Trial in Healthy Women (2002) (129)
Carcinoma of the cervix uteri (2003) (128)
Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary. (1986) (126)
Cancer in women (2003) (125)
Long‐term follow‐up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer (2003) (123)
Secretion of vascular endothelial growth factor in ovarian cancer. (1999) (121)
Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. (2005) (119)
Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. (1989) (119)
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. (2006) (116)
Amplification of c‐erbB2 oncogene (2005) (114)
Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. (2005) (113)
Gestational Trophoblastic Neoplasia (2006) (112)
Time to face the challenge of multimorbidity. A European perspective from the joint action on chronic diseases and promoting healthy ageing across the life cycle (JA-CHRODIS). (2015) (110)
Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy (2004) (110)
HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. (2011) (109)
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. (2009) (105)
Carcinoma of the cervix uteri. (2003) (103)
Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. (2015) (101)
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma (2009) (101)
IN-UTERO TRANSPLANTATION OF PARENTAL CD34 HAEMATOPOIETIC PROGENITOR CELLS IN A PATIENT WITH X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (SCIDXI) (1997) (101)
Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy (2009) (98)
Serum amyloid A (2010) (98)
Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. (2007) (97)
Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management (2011) (97)
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. (2007) (97)
Carcinoma of the Corpus Uteri. (2006) (94)
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. (2006) (93)
Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. (2005) (92)
High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA). (2014) (91)
The Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.The Effect of Debulking Surgery After Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer (1996) (91)
Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. (2000) (90)
Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. (2006) (90)
Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. (2007) (89)
Carcinoma of the Fallopian Tube (2006) (89)
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. (2010) (88)
Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. (2006) (87)
Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy (1998) (83)
Overexpression of claudin‐3 and claudin‐4 receptors in uterine serous papillary carcinoma (2007) (82)
EORTC-GcG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA) (2008) (80)
Interval debulking surgery in advanced epithelial ovarian cancer. (2002) (80)
Histological features of uteroplacental vessels in normal and hypertensive patients in relation to birthweight (1989) (79)
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome (2012) (79)
A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistance and a Potential Target for Therapy in Ovarian Cancer (2011) (78)
Prospective multicenter study on CA 125 in postmenopausal pelvic masses. (1994) (76)
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer. (2001) (74)
Phenotypic and Functional Analysis of Tumor-Infiltrating Lymphocytes Compared with Tumor-Associated Lymphocytes from Ascitic Fluid and Peripheral Blood Lymphocytes in Patients with Advanced Ovarian Cancer (2001) (74)
High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. (2005) (74)
Hormone replacement therapy In breast cancer (1993) (74)
Carcinoma of the Vulva (2003) (71)
Expression of surface antigens during the differentiation of human dendritic cells vs macrophages from blood monocytes in vitro. (1999) (65)
Induction of Ovarian Tumor‐Specific CD8+ Cytotoxic T Lymphocytes by Acid‐Eluted Peptide‐Pulsed Autologous Dendritic Cells (2000) (65)
Cervical cancer staging. (2003) (65)
HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. (2008) (65)
The novel serine protease tumor‐associated differentially expressed gene–15 (matriptase/MT‐SP1) is highly overexpressed in cervical carcinoma (2003) (64)
Eradication of chemotherapy‐resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin (2011) (64)
Early stage cervical cancer: adjuvant treatment in negative lymph node cases. (2007) (63)
Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. (2001) (63)
Radiation‐enhanced expression of E6/E7 transforming oncogenes of human papillomavirus‐16 in human cervical carcinoma (1998) (62)
Toward appropriate criteria in medication adherence assessment in older persons: Position Paper (2016) (59)
Effects of irradiation on the expression of major histocompatibility complex class I antigen and adhesion costimulation molecules ICAM-1 in human cervical cancer. (1997) (59)
Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer (2005) (57)
Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling (2004) (56)
Towards the eradication of HPV infection through universal specific vaccination (2013) (55)
Perspective: Improving Nutritional Guidelines for Sustainable Health Policies: Current Status and Perspectives (2017) (54)
Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC Gynaecological Cancer Cooperative Group study. (1999) (54)
Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence (2017) (54)
miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities (2013) (53)
Investigation of the Ovarian and Prostate Cancer Peptidome for Candidate Early Detection Markers Using a Novel Nanoparticle Biomarker Capture Technology (2010) (53)
Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA (2016) (52)
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients (2017) (51)
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. (2003) (51)
Hearing loss and cognitive decline in older adults: questions and answers (2014) (49)
Public health value of universal HPV vaccination. (2016) (48)
Caring About Women and Cancer (CAWAC): a European survey of the perspectives and experiences of women with female cancers. (1999) (48)
Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference (2015) (47)
Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. (2005) (47)
Carcinoma of the vulva (2003) (47)
In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. (2000) (46)
Ovarian and Fallopian Tube Cancer (2006) (46)
Carcinoma of the vagina (2003) (45)
Uterine serous papillary carcinomas overexpress human trophoblast‐cell‐surface marker (trop‐2) and are highly sensitive to immunotherapy with hRS7, a humanized anti‐trop‐2 monoclonal antibody (2011) (45)
Carcinoma of the Vagina (2006) (45)
The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/Neuropsin/Ovasin) is highly overexpressed in cervical cancer. (2004) (44)
Claudin-7 expression in human epithelial ovarian cancer (2007) (44)
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors (2018) (44)
Basic fibroblast growth factor in ovulatory cycle and postmenopausal human endometrium. (1990) (43)
Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines (2009) (43)
Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas (2008) (43)
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy (2019) (43)
High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. (2011) (42)
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma (2012) (42)
Carcinoma of the vagina. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. (2006) (42)
Induction of tumour-specific CD8+ cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer (2002) (41)
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy (2012) (40)
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer (2009) (40)
Current treatment options for endometrial cancer (2004) (39)
Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study. (2000) (39)
The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells. (2004) (39)
Serum S100A6 Concentration Predicts Peritoneal Tumor Burden in Mice with Epithelial Ovarian Cancer and Is Associated with Advanced Stage in Patients (2009) (38)
Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer (2010) (37)
Advances in dendritic cell-based therapeutic vaccines for cervical cancer (2007) (37)
Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201) (2010) (36)
Effects of cytokines combined with high‐dose gamma irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule‐1 in human ovarian cancers (1996) (36)
Replacement therapy for breast cancer survivors. A pilot study (1995) (36)
Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer (2012) (36)
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody (2011) (36)
Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. (2011) (35)
Effects of irradiation on the expression of surface antigens in human ovarian cancer. (1996) (35)
Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency. (2016) (34)
A new standard of care for treatment of ovarian cancer. (2000) (34)
Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis (2013) (33)
Integrated mutational landscape analysis of uterine leiomyosarcomas (2021) (33)
Overexpression of Clostridium perfringens Enterotoxin Receptors Claudin-3 and Claudin-4 in Uterine Carcinosarcomas (2007) (33)
Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix. (2001) (33)
Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group. (1999) (33)
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor (2011) (32)
Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10. (2002) (32)
Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. (2003) (32)
Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor (2011) (32)
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). (2013) (32)
Influence of Allogeneic Blood Transfusion on Clinical Outcome during Radiotherapy for Cancer of the Uterine Cervix (2003) (31)
Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923). (2003) (31)
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum. (2015) (31)
Mammaglobin B expression in human endometrial cancer (2007) (31)
Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. (2003) (31)
HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas (2012) (30)
Extended radical hysterectomy in early-stage carcinoma of the uterine cervix: tailoring the radicality (1994) (30)
Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. (2001) (30)
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab (2011) (30)
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. (2012) (30)
Differential transforming growth factor-beta secretion in adenocarcinoma and squamous cell carcinoma of the uterine cervix. (1997) (29)
Overexpression of mammaglobin B in epithelial ovarian carcinomas. (2007) (29)
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. (2013) (29)
Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. (1994) (28)
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma (2010) (28)
Reconstitution of T-cell compartment after in utero stem cell transplantation: analysis of T-cell repertoire and thymic output. (2004) (28)
Quality control in multicentric clinical trials. An experience of the EORTC Gynecological Cancer Cooperative Group. (2000) (28)
The effects of irradiation on the expression of a tumour rejection antigen (heat shock protein gp96) in human cervical cancer. (1998) (28)
Cancer in pregnancy: maternal and fetal implications on decision-making. (2011) (27)
Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer (2004) (27)
Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy (2013) (27)
An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin (2015) (27)
What have we learned from ICON1 and ACTION? (2003) (27)
Strategies to Improve Medication Adherence in Older Persons: Consensus Statement from the Senior Italia Federanziani Advisory Board (2016) (27)
Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma: Implications for Immunotherapy With hRS7, a Humanized Anti–Trop-2 Monoclonal Antibody (2011) (27)
Management of Gestational Trophoblastic Disease: Results of a Cooperative Study (1982) (27)
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. (2009) (26)
Clostridium perfringens enterotoxin C‐terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy‐resistant ovarian cancer (2015) (26)
Italian Adults’ Likelihood of Getting COVID-19 Vaccine: A Second Online Survey (2021) (25)
Estro-progestinic replacement therapy modulates the levels of basic fibroblast growth factor (bFGF) in postmenopausal endometrium. (1993) (25)
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes (2009) (25)
High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. (2010) (25)
Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. (1999) (24)
Staging of gynecologic malignancies. (2001) (24)
Prescription drug use among older adults in Italy: a country-wide perspective. (2014) (24)
Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy (2000) (23)
Carcinoma of the ovary. (2001) (23)
Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: Implications for personalized cancer therapy (2015) (23)
The impact of whole-abdomen radiotherapy on survival in advanced ovarian cancer patients with minimal residual disease after chemotherapy (1990) (23)
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence (2009) (23)
FIRST RESULTS OF A RANDOMISED TRIAL COMPARING RADIOTHERAPY VERSUS- OBSERVATION POST OPERATIVELY IN PATIENTS WITH UTERINE SARCOMAS. AN EORTC-GCG STUDY (2003) (23)
Development and Therapeutic Effect of Adoptively Transferred T Cells Primed by Tumor Lysate-Pulsed Autologous Dendritic Cells in a Patient with Metastatic Endometrial Cancer (2000) (23)
Identification of Optimal Reference Genes for Gene Expression Normalization in a Wide Cohort of Endometrioid Endometrial Carcinoma Tissues (2014) (21)
Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium. (2006) (21)
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients (2006) (21)
Final results of After-6 protocol 1: A phase III trial of observation versus 6 courses of paclitaxel (Pac) in advanced ovarian cancer patients in complete response (CR) after platinum-paclitaxel chemotherapy (CT) (2007) (20)
Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. (2006) (20)
HPV vaccination acceptability in young boys. (2013) (20)
Human Kallikrein 5: An Interesting Novel Biomarker in Ovarian Cancer Patients That Elicits Humoral Response (2009) (20)
Follow-up after primary therapy: management of the symptomatic patient-surgery. (1994) (20)
Carcinoma of the fallopian tube (2003) (19)
Clinical trials in patients with epithelial ovarian cancer: past, present and future. (1996) (19)
Development, characterization and distribution of adoptively transferred peripheral blood lymphocytes primed by human papillomavirus 18 E7--pulsed autologous dendritic cells in a patient with metastatic adenocarcinoma of the uterine cervix. (2000) (19)
Restoration of tumor specific human leukocyte antigens class I‐restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer (2004) (19)
The Epidemiology of Cognitive Impairment in the Aging Population: Implications for Hearing Loss (2016) (18)
Effects of retinoic acid combined with irradiation on the expression of major histocompatibility complex molecules and adhesion/costimulation molecules ICAM-1 in human cervical cancer. (1998) (18)
Gynecological sarcomas. (1994) (17)
Why Cancer Staging? (2003) (17)
Caring about women and cancer (CAWAC): a European survey of the perspectives and experiences of women with female cancers (1999) (16)
Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy: Results of an Open Noncomparative Phase 2 Multicenter Italian Study (After-6 Protocol 2) (2009) (16)
Management of early ovarian cancer. (1998) (16)
Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. (2001) (16)
Early stage ovarian cancer: the Italian contribution to clinical research. An update (2001) (15)
Expression of &agr;V-Integrins in Uterine Serous Papillary Carcinomas; Implications for Targeted Therapy With Intetumumab (CNTO 95), a Fully Human Antagonist Anti-&agr;V-Integrin Antibody (2011) (15)
The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines (2016) (15)
Effects of retinoic acid combined with interferon‐gamma on the expression of major‐histocompatibility‐complex molecules and intercellular adhesion molecule‐1 in human cervical cancer (1998) (15)
Treatment of primary invasive cervical cancer. Considerations on 997 consecutive cases. (1988) (14)
Preinvasive Lesions of the Endometrium (1991) (14)
Squamous cell carcinoma of the ovary arising from a mucinous cystic tumor of endocervical (müllerian) type. (2010) (14)
Cisplatin (P), vinblastine (V), and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa cell tumor of the ovary (GCTO): An eortc gynecology cancer cooperative group study (1989) (14)
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis (2017) (13)
Increased levels of interleukin‐10 and transforming growth factor‐β in the plasma and ascitic fluid of patients with advanced ovarian cancer (2001) (13)
Steps forward in regulatory pathways for acute and chronic heart failure (2014) (13)
Consolidation therapies revisited: weekly paclitaxel (2003) (12)
Induction of human tumor‐associated differentially expressed gene‐12 (TADG‐12/TMPRSS3)‐specific cytotoxic T lymphocytes in human lymphocyte antigen‐A2.1–positive healthy donors and patients with advanced ovarian cancer (2009) (12)
Biosimilars: Regulatory Status and Implications across the World (2016) (12)
Retinoic acid up-regulates the expression of major histocompatibility complex molecules and adhesion/costimulation molecules (specifically, intercellular adhesion molecule ICAM-1) in human cervical cancer. (1998) (12)
Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. (2009) (12)
Differential effects of high-dose gamma irradiation on the production of transforming growth factor-beta in fresh and established human ovarian cancer. (1996) (12)
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery (2015) (11)
Ovarial cancer: best timing and applications of debulking surgery. (2000) (11)
Ataxia-telangiectasia and endodermal sinus tumor of the ovary: report of a case. (1988) (11)
Clinical Application of Proteomics in Ovarian Cancer Prevention and Treatment (2012) (11)
Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer. (2002) (11)
New development of the FIGO staging system. (2007) (10)
The role of intervention debulking surgery in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study (1996) (10)
Suboptimal hemoglobin levels: do they impact patients and their therapy? Introduction. (2000) (10)
Suboptimal hemoglobin levels: do they impact patients and their therapy? Audience responses. (2000) (10)
Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer. (2001) (9)
A phase II study of oral gimatecan (ST1481) in women with progressing or recurring advanced epithelial ovarian, fallopian tube and peritoneal cancers. (2006) (9)
Carcinoma of the vagina. (2001) (9)
Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers (2017) (9)
Primary Cervical Carcinoma Cell Lines Overexpress Epithelial Cell Adhesion Molecule (EpCAM) and Are Highly Sensitive to Immunotherapy With MT201, a Fully Human Monoclonal Anti-EpCAM Antibody (2010) (8)
Scaling up health knowledge at European level requires sharing integrated data: an approach for collection of database specification (2016) (8)
Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model. (2015) (8)
FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. (1999) (8)
Development and characterization of an interleukin‐2‐transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules (1996) (8)
PVB chemotherapy in patients with recurrent or advanced dysgerminoma: a Phase II study of the EORTC Gynaecological Cancer Cooperative Group. (1998) (8)
Biological basis of cancer-related anaemia (2001) (7)
Adherence to Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Prescriptions Affects Overall Medication Adherence in Older Persons: Evidence From the Italian Nationwide OsMed Health-DB Database. (2016) (7)
The use of carbon-dioxide laser surgery in the treatment of intraepithelial neoplasia of the uterine cervix. (1999) (7)
Gestational trophoblastic neoplasia. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. (2006) (7)
The surgical staging of ovarian cancer–current practice in 15 European countries (1991) (7)
FIGO staging of gynecologic cancer (1999) (7)
Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix. (2000) (7)
Carcinoma of the Fallopian tube. (2001) (7)
Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in adolescents in Northern Italy: an observational school-based study (2016) (6)
Intervention debulking surgery (IDS) does increase survival in advanced epithelial ovarian cancer (OC); an EORTC gynecological cancer cooperative group (GCCG) study (1993) (6)
Optimizing gemcitabine regimens in ovarian cancer. (2006) (6)
Surgery of advanced malignant epithelial tumours of the ovary. (2000) (6)
Mental health and the global agenda. (2013) (6)
Combination evidence-based therapy is effective in the oldest ‘old patients’ following myocardial infarction. The “Salute e Benessere nell’Anziano” (SeBA) observational study (2016) (6)
Surgical versus chemical upfront debulking in advanced ovarian cancer. (2000) (6)
Radiotherapy following second-look laparotomy in stage III and IV epithelial ovarian cancer treated by chemotherapy: cis-platinum (P) versus cyclophosphamide and cis-platinum (CP) versus cyclophosphamide, adriamycin, and cis-platinum (CAP) (1983) (6)
The introduction of policies for human papillomavirus vaccination in Europe (2008) (6)
Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer (2003) (6)
Uterine serous papillary carcinomas overexpress human trophoblast cell surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody (2011) (5)
The role of collaborative, multistakeholder partnerships in reshaping the health management of patients with noncommunicable diseases during and after the COVID-19 pandemic (2021) (5)
Phase II study of the platinum analog TNO-6 in patients with advanced ovarian cancer. (1986) (5)
Gynaecologic cancers. (1998) (5)
00099 THE SURVIVAL BENEFIT OF INTERVAL DEBULKING SURGERY (IDS) IN ADVANCED OVARIAN CANCER IS MAINTAINED DURING TEN YEARS; THE EORTC GCG 55865 STUDY (2005) (5)
Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8–9, 2007 (2007) (5)
Gestational trophoblastic diseases (2003) (5)
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis (2013) (4)
Clinical application of proteomics in ovarian cancer prevention and treatment. (2009) (4)
The Italian gynecological consensus statement on the use of epoetin alfa in the management of anemia. (2002) (4)
Serum human epididymis protein 4 ( HE 4 ) and Risk for Ovarian Malignancy Algorithm ( ROMA ) as new diagnostic and prognostic tools for epithelial ovarian cancer management (2011) (4)
Steps forward in regulatory pathways for acute and chronic heart failure (2015) (3)
Why cancer staging? FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. (2006) (3)
Phase II study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: an EORTC Gynecological cancer Cooperative Group study (1991) (3)
Well-Being and Mental Wellness (2020) (3)
Integration of new or experimental treatment options and new approaches to clinical trials. (2005) (3)
Vincristine, bleomycin, mitomycin C, cisplatin combination chemotherapy as additive treatment to radiotherapy in poor risk patients with squamous cell carcinoma of the uterine cervix. (1985) (3)
Development and in vitro characterization of a GM-CSF secreting human ovarian carcinoma tumor vaccine (1995) (3)
Carcinoma of the vulva. (2003) (3)
HER‐2/neu overexpression and amplification in uterine serous papillary carcinoma (2007) (3)
Hormone replacement therapy in gynecological cancer survivors. (1998) (3)
COVID-19 vaccine literacy: A scoping review (2023) (3)
Cancer of the Ovary and Fallopian Tube (2003) (2)
Effects of retinoic acid on the expression of a tumor rejection antigen (heat shock protein gp96) in human cervical cancer. (1998) (2)
Esorubicin in advanced ovarian epithelial cancer. A phase II study of the EORTC Gynecological Cancer Cooperative Group. (1988) (2)
Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA (2016) (2)
A randomized phase II study assessing an optimized schedule of oregovomab (O) anti-CA125 vaccination with carboplatin paclitaxel (CP) relative to CP alone in front-line treatment of optimally cytoreduced stage III/IV ovarian cancer (EOC). (2017) (2)
AFTER TEN YEARS FOLLOW-UP INTERVAL DEBULKING SURGERY REMAINS A SIGNIFICANT PROGNOSTIC FACTOR FOR SURVIVAL AND PROGRESSION FREE SURVIVAL FOR ADVANCED OVARIAN CANCER: THE EORTC GYNAECOLOGICAL CANCER GROUP STUDY (2004) (2)
Discussion: Current Issues in the Design of Ovarian Cancer Treatment Trials (2003) (2)
Adjuvant therapy in stage-I epithelial ovarian cancer: an open question. (1994) (2)
Prospective multicenter study on the clinical utility of ca-72.4 in postmenopausal patients with pelvic mass. (1995) (2)
Gestational trophoblastic diseases. (2003) (2)
Abstract 5656: Quantitative measurement of PDL1 expression across tumor types using laser capture microdissection and reverse phase protein microarray (2017) (2)
Successful application of indirect in‐situ polymerase chain reaction to tissues fixed in Bouin's solution (1999) (1)
European Innovation Partnership on Active and Healthy Ageing. From Plan to Action. (2012) (1)
0009: Extending the Platinum-Free Interval (PFI) with a Non-Platinum Therapy in Platinum (P)-Sensitive Recurrent Ovarian Cancer (Oc): Results From the Socrates Retrospective Study (2006) (1)
Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer (2003) (1)
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis (2013) (1)
Prognostic factor in advanced epithelial ovarian cancer (EOC) analysis of a cooperative group experience (1986) (1)
Expression and cytokine mediated modulation of adhesion/costimulation molecules ICAM‐1(CD54) and LFA‐3(CD58) in human ovarian cancer (1997) (1)
Chlamydia trachomatis genotypes in school adolescents, Italy (2015) (1)
Prospective study on the clinical utility of CA 125 and CA 72-4 in preoperative diagnosis of postmenopausal patients with pelvic masses. (1995) (1)
EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials (2012) (1)
Abstract 364: In vivo targeting of CD44+ ovarian cancer stem cells (CSC) by Clostridium Perfringens Enterotoxin binding domain (CPE-peptide) conjugated to poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NP) (2012) (1)
Generic and biosilimilar medicines use and expenditure: A report from the National Observatory on the Use of Medicines (OsMed) of the Italian Medicines Agency (AIFA) (2015) (1)
Treatment of advanced ovarian cancer (OC): A randomized trial comparing different platinum (P) combinations (1986) (1)
0348: Phase I Dose Escalation Trial of Hpv16/18 E7-Pulsed Dendritic Cell Vaccination in Stage Ib-Iia Cervical Cancer Patients (2006) (1)
Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium. (2003) (1)
A phase II study of the combination of liposomal doxorubicin (LD) and gemcitabine (G) in patients with relapsed ovarian cancer after chemotherapy containing platinum compounds (2005) (1)
Well-Being and Mental Wellness-Oxford Research Encyclopedia of Global Public Health (2020) (1)
Consensus Statement A new standard of care for treatment of ovarian cancer (2000) (1)
Supplementary Table 2b (2013) (1)
Supplementary Table 4a (2013) (1)
8040 POSTER Diagnostic and Prognostic Significance of CA125 and HE4 in Ovarian Cancer Patients (2011) (0)
1315 Clinical role of human epididymis protein 4 (HE4) in epithelial ovarian cancer (2009) (0)
Development and characterization of an interleukin-2-transduced human ovarian carcinoma vaccine not expressing major histocompatibility complex molecules tumor (2004) (0)
Supplementary Table 1a (2013) (0)
Claudin-3 and Claudin-4: New targets for the treatment of chemotherapy resistant uterine serous papillary carcinoma using clostridium perfringens enterotoxin (2006) (0)
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients (2017) (0)
Current status and treatment of endometrial cancer (1997) (0)
[Advanced cancer of the ovary. The paclitaxel-cisplatin combination as the first-line standard of treatment]. (1999) (0)
Abstract 732: Iron oxide nanoparticles functionalized with the Clostridium Perfringens Enterotoxin carboxi-terminal fragment peptide: A novel diagnostic and therapeutic approach to specifically target ovarian cancer. (2013) (0)
Title Differential effects of high-dose gamma irradiation on the production of transforming growth factor-beta in fresh and established human ovarian cancer (1996) (0)
Protein network mapping of glucose metabolism in ovarian cancer. (2014) (0)
1459 POSTER HE4 Levels in Endometrial Cancer Patients – Potential Role as a Tumour Biomarker (2011) (0)
Abstract B18: miRNA landscape analysis of stage I EOC, identifies miR-199a-5p associated to poor prognosis in grade 3 subgroup (2013) (0)
Mammaglobin B (SCGB2A1)-specific CD8+ cytotoxic T lymphocytes (CTL) are highly effective in killing autologous chemotherapy resistant ovarian cancer cells: Implications for SCGB2A1 dendritic cell-based therapeutic vaccines (2012) (0)
[Metroplasty using Tomkins' method. Clinico-statistical study]. (1978) (0)
Supplementary Table 3a (2013) (0)
HPV16/18 E7-PULSED DENDRITIC CELL VACCINATION IN PATIENTS WITH RECURRENT CERVICAL CANCER REFRACTORY TO STANDARD SALVAGE THERAPY (2004) (0)
ublic health value of universal HPV vaccination (2015) (0)
An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin (2015) (0)
Latest Top 20 Read Articles (2015) (0)
[Medullary carcinoma of the thyroid with diarrhea and tetany]. (1968) (0)
RACIAL DIFFERENCES IN OVEREXPRESSION OF EPIDERMAL GROWTH FACTOR TYPE II RECEPTOR (HER2/ NEU): A MAJOR PROGNOSTIC INDICATOR AND NOVEL THERAPEUTIC TARGET IN UTERINE SEROUS PAPILLARY CANCER (2004) (0)
Supplementary Table 3b (2013) (0)
Evolving strategies in adjuvant treatment for stage IB cervical cancer after radical hysterectomy (1999) (0)
From the Editor (2006) (0)
HPV Vaccination Concepts in the Reality of Today (2019) (0)
Pro-Angiogenetic Effects of Purified Extracts from Helix aspersa during Zebrafish Development (2022) (0)
PROGNOSTIC VALUE OF SERUM CA125 AND MARKER HALF-LIFE (T½) FOR LONG-TERM PROGRESSION FREE AND OVERALL SURVIVAL AND OPTIMAL INTERVAL DEBULKING SURGERY (IDS) IN ADVANCED OVARIAN CARCINOMA. A EORTC-GCG STUDY (2004) (0)
On behalf of the A 1 Action group “ Prescription and Adherence to Medical Plans ” , european innovation Partnership on Active and Healthy (2015) (0)
Why cancer staging? (2003) (0)
[Radiotherapy and surgical treatment of cervix carcinoma]. (1980) (0)
From the editor (2003) (0)
Risks and benefits of hormone replacement therapy (1998) (0)
Author ' s response to reviews Title : Mammaglobin B expression is an independent prognostic marker for reduced risk of recurrence in epithelial ovarian cancer (2009) (0)
P-402: Advanced age and medication prescription (2015) (0)
Contents Vol. 51, 2001 (2001) (0)
Subject Index Vol. 51, 2001 (2001) (0)
The effect of intraperitoneal administration of clostridium perfringens enterotoxin on chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice. (2011) (0)
515 Phase II study of cisplatin (P), vinblastine (V) and bleomycin (B) in recurrent or advanced dysgerminoma (D) (1995) (0)
EXPRESSION PATTERN AND MOLECULAR FUNCTION OF TRASCRIPTION FACTOR FOXM1(FORKHEAD BOX PROTEIN M1) IN EPITHELIAL OVARIAN CANCER CLINICALSPECIMENS AND CELL LINES (2013) (0)
[Significance of the cyto-histologic grading of stage I and II epithelial tumors of the ovary]. (1984) (0)
0047: Claudin-3 and Claudin-4 Receptor Overexpression: Novel Targets for a Type Specific Therapy Against Uterine Serous Papillary Carcinomas Using Clostridium Perfringens Enterotoxin (2006) (0)
8016 Gene expression profile as a diagnostic tool for synchronous ovarian/endometrial cancer (2009) (0)
PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version (2006) (0)
Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer? (2007) (0)
[Criteria for the clinical management of vesicular mole. A polycentric study of 383 cases]. (1982) (0)
Quality control (QC) in multicentric clinical trials (MCT) (1992) (0)
Supplementary Table 4b (2013) (0)
Protein network mapping of platinum-resistant and poor-survival ovarian cancer. (2013) (0)
Biological age: reflections ahead of the FMSI Congress (2023) (0)
Clinical Approach to Adnexal Disease (2009) (0)
0178: Oral Gimatecan in Women with Progressing or Recurring Advanced Epithelial Ovarian, Fallopian Tube and Peritoneal Cancers (2006) (0)
variant is a biomarker of poor outcome, platinum resistance and a potential target for therapy in ovarian cancer. (2016) (0)
Abstracts of the Annual Meeting of the Swiss Society for Oncology, Basel, March 1983 (2004) (0)
881 MicroRNA Expression Profiling of Stage I Ovarian Carcinoma Reveals Signatures Characterizing the Different Tumor Grades and Histotypes (2012) (0)
PCV153 HOW COSTLY IS POOR ADHERENCE TO PHARMACOLOGICAL TREATMENTS FOR CARDIOVASCULAR DISEASE? A SYSTEMATIC LITERATURE REVIEW (2019) (0)
Potential therapeutic activity of adecatumumab (MT201), a fully human monoclonal antibody, against epithelial cell adhesion molecule (EpCAM) in uterine serous papillary carcinoma. (2016) (0)
Abstract 699: Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody (2010) (0)
Risk categories in stage IB cervical cancer (1989) (0)
Cisplatin and mitomycin C based combination chemotherapy in locally advanced and metastatic squamous cell carcinoma of the uterine cervix: experiences of the EORTC gynecological cancer cooperative group (1991) (0)
5014 POSTER Evaluations on the natural history of human papillomaviruses infections and related diseases in HIV-seropositive women (2007) (0)
prognostic marker for reduced risk of recurrence in epithelial ovarian cancer (2009) (0)
[Specific determination of plasma hCG]. (1977) (0)
00086 ANALYSIS OF GENE EXPRESSION PATTERNS THAT DEFINES SEROUS PAPILLARY OVARIAN CARCINOMAS (2005) (0)
Human Kallikrein 5: An Interesting Novel Biomarker in Ovarian Cancer Patients that Elicits a Humoral Response (2009) (0)
[Radio-surgical treatment of cervical carcinoma]. (1978) (0)
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis (2017) (0)
Abstract 4369: Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in C.B-17/SCID mice by intraperitoneal administration of Clostridium Perfringens Enterotoxin (CPE) (2011) (0)
Italian national multicentric study on post-menopausal pelvic masses (1993) (0)
[Human chorionic somatommamotropins (HCS or HPL) : radioimmunologic determination and clinical significance]. (1975) (0)
172 Trefoil factor 3: a potential diagnostic and prognostic marker whose expression contributes to malignant feature in endometrial carcinoma cells (2010) (0)
Medical-health recommendations for the Serie A League (2021) (0)
Latest Top 20 Read Articles (2015) (0)
509 Evaluation of Human Epididymis Protein 4 in endometrial cancer patients (2010) (0)
Supplementary Table 2a (2013) (0)
Conservative treatment in non-epithelial ovarian cancer (NEOC) (1989) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Sergio L. Pecorelli?

Sergio L. Pecorelli is affiliated with the following schools: